Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database
Open Access
- 27 February 2008
- journal article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 8 (1), 21
- https://doi.org/10.1186/1471-2334-8-21
Abstract
Background: Guidelines established for the treatment of HIV-1 infection and genotype interpretation do not apply for HIV-2. Data about antiretroviral (ARV) drug efficacy and resistance mutations is scarce.Methods: Clinical data about HIV-2 infected patients in Belgium and Luxembourg were collected and the effect of ARV therapy on plasma viral load and CD4 counts were analysed. Viral RNA encoding for protease (PR) and reverse transcriptase (RT) from ARV-naïve and treated patients were sequenced.Results: Sixty-five HIV-2 infected patients were included in this cohort. Twenty patients were treated with 25 different ARV combinations in a total of 34 regimens and six months after the start of ARV therapy, only one third achieved viral load suppression. All of these successful regimens bar one contained protease inhibitors (PIs). Mean CD4 gains in the group of viral load suppressors and the group of patients treated with PI-containing regimens were respectively significantly higher than in the group of non-suppressors and the group of PI-sparing regimens. The most frequent mutations selected under therapy (compared to HIV-2 ROD) were V71I, L90M and I89V within PR. Within RT, they were M184V, Q151M, V111I and K65R. All of these mutations, except K65R and M184V, were also found in variable proportions in ARV-naïve patients.Conclusion: Despite a high rate of ARV treatment failure, better virological and immunological results were achieved with PI-containing regimens. The analysis of polymorphic positions and HIV-2 specific mutations selected during therapy showed for the first time that transmission of drug resistant viruses has occurred in Belgium and Luxembourg. The high heterogeneity in ARV combinations reflects a lack of guidelines for the treatment of HIV-2 infection.Keywords
This publication has 44 references indexed in Scilit:
- Long‐Term Intrapatient Viral Evolution during HIV‐2 InfectionThe Journal of Infectious Diseases, 2007
- Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2007
- HIV-1 and HIV-2 prevalence and associated risk factors among postnatal women in Harare, ZimbabweEpidemiology and Infection, 2007
- Quantitative Detection of Plasma Human Immunodeficiency Virus Type 2 Subtype A RNA by the Nuclisens EasyQ Assay (Version 1.1)Journal of Clinical Microbiology, 2007
- Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The GambiaAIDS, 2006
- Évaluation de l'efficacité et de la tolérance du traitement antirétroviral chez des patients infectés par le VIH-2 à Dakar : étude préliminaireMedecine Et Maladies Infectieuses, 2006
- Equal Plasma Viral Loads Predict a Similar Rate of CD4+T Cell Decline in Human Immunodeficiency Virus (HIV) Type 1– and HIV‐2–Infected Individuals from Senegal, West AfricaThe Journal of Infectious Diseases, 2002
- Antiviral Resistance of Biologic HIV-2 Clones Obtained From Individuals on Nucleoside Reverse Transcriptase Inhibitor TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Reduced Rate of Disease Development After HIV-2 Infection as Compared to HIV-1Science, 1994
- Human Immunodeficiency Virus Type 2 Infection Associated with AIDS in West AfricaNew England Journal of Medicine, 1987